ID   PRDM5_HUMAN             Reviewed;         630 AA.
AC   Q9NQX1; Q0VAI9; Q0VAJ0; Q6NXQ7;
DT   16-NOV-2001, integrated into UniProtKB/Swiss-Prot.
DT   04-NOV-2008, sequence version 2.
DT   28-JUN-2023, entry version 190.
DE   RecName: Full=PR domain zinc finger protein 5;
DE            EC=2.1.1.-;
DE   AltName: Full=PR domain-containing protein 5;
GN   Name=PRDM5; Synonyms=PFM2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=15077163; DOI=10.1038/sj.onc.1207615;
RA   Deng Q., Huang S.;
RT   "PRDM5 is silenced in human cancers and has growth suppressive
RT   activities.";
RL   Oncogene 23:4903-4910(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2; 3 AND 4).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   TISSUE SPECIFICITY.
RX   PubMed=17699856; DOI=10.1158/1078-0432.ccr-07-0305;
RA   Watanabe Y., Toyota M., Kondo Y., Suzuki H., Imai T., Ohe-Toyota M.,
RA   Maruyama R., Nojima M., Sasaki Y., Sekido Y., Hiratsuka H., Shinomura Y.,
RA   Imai K., Itoh F., Tokino T.;
RT   "PRDM5 identified as a target of epigenetic silencing in colorectal and
RT   gastric cancer.";
RL   Clin. Cancer Res. 13:4786-4794(2007).
RN   [6]
RP   FUNCTION, INTERACTION WITH EHMT2; GFI1 AND HDAC1, AND SUBCELLULAR LOCATION.
RX   PubMed=17636019; DOI=10.1128/mcb.00762-07;
RA   Duan Z., Person R.E., Lee H.-H., Huang S., Donadieu J., Badolato R.,
RA   Grimes H.L., Papayannopoulou T., Horwitz M.S.;
RT   "Epigenetic regulation of protein-coding and microRNA genes by the Gfi1-
RT   interacting tumor suppressor PRDM5.";
RL   Mol. Cell. Biol. 27:6889-6902(2007).
RN   [7]
RP   VARIANT BCS2 CYS-107, AND FUNCTION.
RX   PubMed=21664999; DOI=10.1016/j.ajhg.2011.05.007;
RA   Burkitt Wright E.M., Spencer H.L., Daly S.B., Manson F.D., Zeef L.A.,
RA   Urquhart J., Zoppi N., Bonshek R., Tosounidis I., Mohan M., Madden C.,
RA   Dodds A., Chandler K.E., Banka S., Au L., Clayton-Smith J., Khan N.,
RA   Biesecker L.G., Wilson M., Rohrbach M., Colombi M., Giunta C., Black G.C.;
RT   "Mutations in PRDM5 in brittle cornea syndrome identify a pathway
RT   regulating extracellular matrix development and maintenance.";
RL   Am. J. Hum. Genet. 88:767-777(2011).
CC   -!- FUNCTION: Sequence-specific DNA-binding transcription factor. Represses
CC       transcription at least in part by recruitment of the histone
CC       methyltransferase EHMT2/G9A and histone deacetylases such as HDAC1.
CC       Regulates hematopoiesis-associated protein-coding and microRNA (miRNA)
CC       genes. May regulate the expression of proteins involved in
CC       extracellular matrix development and maintenance, including fibrillar
CC       collagens, such as COL4A1 and COL11A1, connective tissue components,
CC       such as HAPLN1, and molecules regulating cell migration and adhesion,
CC       including EDIL3 and TGFB2. May cause G2/M arrest and apoptosis in
CC       cancer cells. {ECO:0000269|PubMed:15077163,
CC       ECO:0000269|PubMed:17636019, ECO:0000269|PubMed:21664999}.
CC   -!- SUBUNIT: Interacts with EHMT2/G9A, GFI1 and HDAC1.
CC       {ECO:0000269|PubMed:17636019}.
CC   -!- INTERACTION:
CC       Q9NQX1; Q96KQ7: EHMT2; NbExp=3; IntAct=EBI-4292031, EBI-744366;
CC       Q9NQX1; Q99684: GFI1; NbExp=2; IntAct=EBI-4292031, EBI-949368;
CC       Q9NQX1; Q13547: HDAC1; NbExp=3; IntAct=EBI-4292031, EBI-301834;
CC       Q9NQX1-2; Q9NX46: ADPRS; NbExp=3; IntAct=EBI-12859340, EBI-718580;
CC       Q9NQX1-2; P35523: CLCN1; NbExp=3; IntAct=EBI-12859340, EBI-10206780;
CC       Q9NQX1-2; Q6NZ36-4: FAAP20; NbExp=3; IntAct=EBI-12859340, EBI-12013806;
CC       Q9NQX1-2; Q9H4M3-2: FBXO44; NbExp=3; IntAct=EBI-12859340, EBI-12104696;
CC       Q9NQX1-2; Q9Y272: RASD1; NbExp=3; IntAct=EBI-12859340, EBI-740818;
CC       Q9NQX1-2; P29597: TYK2; NbExp=3; IntAct=EBI-12859340, EBI-1383454;
CC       Q9NQX1-2; P32241: VIPR1; NbExp=3; IntAct=EBI-12859340, EBI-3917984;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15077163,
CC       ECO:0000269|PubMed:17636019}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q9NQX1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NQX1-2; Sequence=VSP_035654;
CC       Name=3;
CC         IsoId=Q9NQX1-3; Sequence=VSP_035652, VSP_035653;
CC       Name=4;
CC         IsoId=Q9NQX1-4; Sequence=VSP_035654, VSP_054395, VSP_054396;
CC   -!- TISSUE SPECIFICITY: Widely expressed with highest levels in colon and
CC       ovary. Tends to be silenced in breast, colorectal, gastric and liver
CC       cancer tissues. {ECO:0000269|PubMed:15077163,
CC       ECO:0000269|PubMed:17699856}.
CC   -!- DISEASE: Brittle cornea syndrome 2 (BCS2) [MIM:614170]: A disorder
CC       characterized by extreme corneal thinning resulting in corneal rupture
CC       after minor trauma, blue sclerae, keratoconus or keratoglobus,
CC       hyperelasticity of the skin, and hypermobile joints.
CC       {ECO:0000269|PubMed:21664999}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the class V-like SAM-binding methyltransferase
CC       superfamily. {ECO:0000255|PROSITE-ProRule:PRU00190}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF272897; AAF78077.1; -; mRNA.
DR   EMBL; AK056352; BAG51686.1; -; mRNA.
DR   EMBL; AC025741; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104068; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104795; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC066942; AAH66942.1; -; mRNA.
DR   EMBL; BC121037; AAI21038.1; -; mRNA.
DR   EMBL; BC121038; AAI21039.1; -; mRNA.
DR   CCDS; CCDS3716.1; -. [Q9NQX1-1]
DR   CCDS; CCDS75187.1; -. [Q9NQX1-4]
DR   CCDS; CCDS75188.1; -. [Q9NQX1-2]
DR   RefSeq; NP_001287752.1; NM_001300823.1. [Q9NQX1-2]
DR   RefSeq; NP_001287753.1; NM_001300824.1. [Q9NQX1-4]
DR   RefSeq; NP_061169.2; NM_018699.3. [Q9NQX1-1]
DR   PDB; 6XAZ; X-ray; 1.70 A; A/B=1-127.
DR   PDBsum; 6XAZ; -.
DR   AlphaFoldDB; Q9NQX1; -.
DR   SMR; Q9NQX1; -.
DR   BioGRID; 116287; 57.
DR   IntAct; Q9NQX1; 49.
DR   MINT; Q9NQX1; -.
DR   STRING; 9606.ENSP00000264808; -.
DR   MoonDB; Q9NQX1; Predicted.
DR   GlyGen; Q9NQX1; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9NQX1; -.
DR   PhosphoSitePlus; Q9NQX1; -.
DR   SwissPalm; Q9NQX1; -.
DR   BioMuta; PRDM5; -.
DR   DMDM; 212276458; -.
DR   MassIVE; Q9NQX1; -.
DR   PaxDb; Q9NQX1; -.
DR   PeptideAtlas; Q9NQX1; -.
DR   ProteomicsDB; 58796; -.
DR   ProteomicsDB; 82218; -. [Q9NQX1-1]
DR   ProteomicsDB; 82219; -. [Q9NQX1-2]
DR   ProteomicsDB; 82220; -. [Q9NQX1-3]
DR   Antibodypedia; 26690; 278 antibodies from 29 providers.
DR   DNASU; 11107; -.
DR   Ensembl; ENST00000264808.8; ENSP00000264808.3; ENSG00000138738.11. [Q9NQX1-1]
DR   Ensembl; ENST00000394435.2; ENSP00000377955.2; ENSG00000138738.11. [Q9NQX1-3]
DR   Ensembl; ENST00000428209.6; ENSP00000404832.2; ENSG00000138738.11. [Q9NQX1-2]
DR   Ensembl; ENST00000515109.5; ENSP00000422309.1; ENSG00000138738.11. [Q9NQX1-4]
DR   GeneID; 11107; -.
DR   KEGG; hsa:11107; -.
DR   MANE-Select; ENST00000264808.8; ENSP00000264808.3; NM_018699.4; NP_061169.2.
DR   UCSC; uc003idn.4; human. [Q9NQX1-1]
DR   AGR; HGNC:9349; -.
DR   CTD; 11107; -.
DR   DisGeNET; 11107; -.
DR   GeneCards; PRDM5; -.
DR   HGNC; HGNC:9349; PRDM5.
DR   HPA; ENSG00000138738; Low tissue specificity.
DR   MalaCards; PRDM5; -.
DR   MIM; 614161; gene.
DR   MIM; 614170; phenotype.
DR   neXtProt; NX_Q9NQX1; -.
DR   OpenTargets; ENSG00000138738; -.
DR   Orphanet; 90354; Brittle cornea syndrome.
DR   PharmGKB; PA33717; -.
DR   VEuPathDB; HostDB:ENSG00000138738; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   eggNOG; KOG2461; Eukaryota.
DR   GeneTree; ENSGT00940000158340; -.
DR   HOGENOM; CLU_002678_75_0_1; -.
DR   InParanoid; Q9NQX1; -.
DR   OMA; YKNHKKX; -.
DR   OrthoDB; 688990at2759; -.
DR   PhylomeDB; Q9NQX1; -.
DR   TreeFam; TF106478; -.
DR   PathwayCommons; Q9NQX1; -.
DR   SignaLink; Q9NQX1; -.
DR   BioGRID-ORCS; 11107; 6 hits in 1178 CRISPR screens.
DR   ChiTaRS; PRDM5; human.
DR   GenomeRNAi; 11107; -.
DR   Pharos; Q9NQX1; Tbio.
DR   PRO; PR:Q9NQX1; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; Q9NQX1; protein.
DR   Bgee; ENSG00000138738; Expressed in calcaneal tendon and 126 other tissues.
DR   ExpressionAtlas; Q9NQX1; baseline and differential.
DR   Genevisible; Q9NQX1; HS.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IBA:GO_Central.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IDA:UniProtKB.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008168; F:methyltransferase activity; IEA:UniProtKB-KW.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:UniProtKB.
DR   GO; GO:1990830; P:cellular response to leukemia inhibitory factor; IEA:Ensembl.
DR   GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW.
DR   GO; GO:0032259; P:methylation; IEA:UniProtKB-KW.
DR   GO; GO:0000278; P:mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:ARUK-UCL.
DR   GO; GO:1903053; P:regulation of extracellular matrix organization; IMP:ARUK-UCL.
DR   CDD; cd19190; PR-SET_PRDM5; 1.
DR   Gene3D; 3.30.160.60; Classic Zinc Finger; 13.
DR   Gene3D; 2.170.270.10; SET domain; 1.
DR   InterPro; IPR044415; PRDM5_PR-SET.
DR   InterPro; IPR001214; SET_dom.
DR   InterPro; IPR046341; SET_dom_sf.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   InterPro; IPR017125; Znf_PRDM5-like.
DR   PANTHER; PTHR24404:SF82; RH47711P-RELATED; 1.
DR   PANTHER; PTHR24404; ZINC FINGER PROTEIN; 1.
DR   Pfam; PF00096; zf-C2H2; 10.
DR   Pfam; PF13912; zf-C2H2_6; 2.
DR   Pfam; PF12874; zf-met; 3.
DR   PIRSF; PIRSF037162; PRDM; 1.
DR   SMART; SM00317; SET; 1.
DR   SMART; SM00355; ZnF_C2H2; 16.
DR   SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 8.
DR   SUPFAM; SSF82199; SET domain; 1.
DR   PROSITE; PS50280; SET; 1.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 14.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 16.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Chromatin regulator;
KW   Disease variant; DNA-binding; Metal-binding; Methyltransferase; Nucleus;
KW   Reference proteome; Repeat; Repressor; S-adenosyl-L-methionine;
KW   Transcription; Transcription regulation; Transferase; Zinc; Zinc-finger.
FT   CHAIN           1..630
FT                   /note="PR domain zinc finger protein 5"
FT                   /id="PRO_0000047761"
FT   DOMAIN          8..124
FT                   /note="SET"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00190"
FT   ZN_FING         167..190
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         199..221
FT                   /note="C2H2-type 2; atypical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         234..256
FT                   /note="C2H2-type 3; atypical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         262..287
FT                   /note="C2H2-type 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         295..317
FT                   /note="C2H2-type 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         320..342
FT                   /note="C2H2-type 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         348..370
FT                   /note="C2H2-type 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         376..398
FT                   /note="C2H2-type 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         404..426
FT                   /note="C2H2-type 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         432..455
FT                   /note="C2H2-type 10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         461..483
FT                   /note="C2H2-type 11"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         489..511
FT                   /note="C2H2-type 12"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         517..539
FT                   /note="C2H2-type 13"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         545..567
FT                   /note="C2H2-type 14"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         573..595
FT                   /note="C2H2-type 15"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         602..625
FT                   /note="C2H2-type 16"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   VAR_SEQ         101..111
FT                   /note="EGENIFYLAVE -> DKNLGPAEWRG (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_035652"
FT   VAR_SEQ         112..630
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_035653"
FT   VAR_SEQ         218..248
FT                   /note="Missing (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_035654"
FT   VAR_SEQ         515..532
FT                   /note="RPYQCPYCEKGFSKNDGL -> AVQVLRVQQGLQPEARPG (in isoform
FT                   4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_054395"
FT   VAR_SEQ         533..630
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_054396"
FT   VARIANT         107
FT                   /note="Y -> C (in BCS2; dbSNP:rs387907111)"
FT                   /evidence="ECO:0000269|PubMed:21664999"
FT                   /id="VAR_066393"
FT   CONFLICT        261
FT                   /note="R -> K (in Ref. 1; AAF78077)"
FT                   /evidence="ECO:0000305"
FT   STRAND          4..6
FT                   /evidence="ECO:0007829|PDB:6XAZ"
FT   STRAND          10..14
FT                   /evidence="ECO:0007829|PDB:6XAZ"
FT   STRAND          16..27
FT                   /evidence="ECO:0007829|PDB:6XAZ"
FT   STRAND          41..43
FT                   /evidence="ECO:0007829|PDB:6XAZ"
FT   STRAND          57..61
FT                   /evidence="ECO:0007829|PDB:6XAZ"
FT   STRAND          67..72
FT                   /evidence="ECO:0007829|PDB:6XAZ"
FT   HELIX           76..78
FT                   /evidence="ECO:0007829|PDB:6XAZ"
FT   HELIX           81..84
FT                   /evidence="ECO:0007829|PDB:6XAZ"
FT   TURN            91..93
FT                   /evidence="ECO:0007829|PDB:6XAZ"
FT   STRAND          96..101
FT                   /evidence="ECO:0007829|PDB:6XAZ"
FT   STRAND          104..109
FT                   /evidence="ECO:0007829|PDB:6XAZ"
FT   STRAND          120..122
FT                   /evidence="ECO:0007829|PDB:6XAZ"
SQ   SEQUENCE   630 AA;  73090 MW;  D16AF81AB5A34398 CRC64;
     MLGMYVPDRF SLKSSRVQDG MGLYTARRVR KGEKFGPFAG EKRMPEDLDE NMDYRLMWEV
     RGSKGEVLYI LDATNPRHSN WLRFVHEAPS QEQKNLAAIQ EGENIFYLAV EDIETDTELL
     IGYLDSDMEA EEEEQQIMTV IKEGEVENSR RQSTAGRKDR LGCKEDYACP QCESSFTSED
     ILAEHLQTLH QKPTEEKEFK CKNCGKKFPV KQALQRHVLQ CTAKSSLKES SRSFQCSVCN
     SSFSSASSFE QHQETCRGDA RFVCKADSCG KRLKSKDALK RHQENVHTGD PKKKLICSVC
     NKKCSSASSL QEHRKIHEIF DCQECMKKFI SANQLKRHMI THSEKRPYNC EICNKSFKRL
     DQVGAHKVIH SEDKPYKCKL CGKGFAHRNV YKNHKKTHSE ERPFQCEECK ALFRTPFSLQ
     RHLLIHNSER TFKCHHCDAT FKRKDTLNVH VQVVHERHKK YRCELCNKAF VTPSVLRSHK
     KTHTGEKEKI CPYCGQKFAS SGTLRVHIRS HTGERPYQCP YCEKGFSKND GLKMHIRTHT
     REKPYKCSEC SKAFSQKRGL DEHKRTHTGE KPFQCDVCDL AFSLKKMLIR HKMTHNPNRP
     LAECQFCHKK FTRNDYLKVH MDNIHGVADS
//
